“In the short term, the market is a popularity contest. In the long term, the market is a weighing machine.” -Warren Buffett
In the world of over-the-counter stocks, the “popularity contest” can sometimes overlook reality. Traders and speculators often see the OTC Markets landscape as a place for short-term gains, scouring for stock flipping opportunities. However, this style of trading can often overlook the true value and reality of a company’s underlying value.
One company that will soon benefit from the “weighing machine,” is Innovest Global, Inc. (OTC Pink: IVST).
IVST: Massive Acquisition Pipeline, Existing Divisions Performing Extremely Well
Innovest Global, Inc. (OTC Pink: IVST) is a Cleveland, OH-based conglomerate that operates across biotechnology, health sciences, durable goods, and commercial & industrial energy. Currently, the company’s Commercial & Industrial Energy Division is generating baseline quarterly revenues of $800,000.
Furthermore, Innovest Global, Inc. (OTC Pink: IVST)’s Biotech & Health Sciences Division is expected to be officially launched shortly, once the previously-announced 20% stake acquisition in StemVax Therapeutics, LLC closes. StemVax is currently developing a brain cancer vaccine specifically for the treatment of glioblastomas. World-renowned neuroscientist, Dr. Dwain Morris-Irvin will lead the new biotech division, bringing massive insight and potential.
This comes as management just recently disclosed that its acquisition pipeline is stuffed full with fourteen different companies across a wide range of industries, including its existing divisions. Innovest Global, Inc. (OTC Pink: IVST) is currently undergoing a two-year PCAOB audit by NMS, Inc. in order to begin management’s vision to uplist to higher exchanges.
Industry Outlook
Innovest Global, Inc. (OTC Pink: IVST)’s existing outlook looks extremely bright when considering its current businesses and their industry forecasts.
Commercial Energy: According to the market research firm, Renub Research, the global LED lighting market is forecast to surpass $100 billion by the end of 2024. Renub credits the growth due to global urbanization and growing focus on energy efficiency.
Biotechnology: According to Grand View Research, the global brain tumor diagnostics and therapeutics market is forecast to reach $773.10 million by 2025. The market research firm notes that the “lucrative growth” comes from “increasing incidence of various brain cancers, particularly glioblastoma.”
IVST: Q1 Earnings Beat Management Estimates, 50 Million Common Shares Cancelled
On April 16, 2018, Innovest Global, Inc. (OTC Pink: IVST) released first quarter earnings, which featured total revenues of over $708,000 and gross profit of just under $330,000. The company reported total current assets of $932,096 and total current liabilities of $352,165, giving the company a strong quick ratio of 2.60, which is four times stronger than the conglomerate industry average of 0.60.
“The response we are getting from business and technology owners that want to get to the next level is very encouraging,” said Innovest CEO, Dan Martin. “We are incrementally increasing the size of the organizations we are looking to acquire and seeing great progress.”
Management also announced that it has cancelled 50 million common shares, as a result the new Innovest Global, Inc. (OTC Pink: IVST) share structure is now:
Authorized Shares: 500 Million
Outstanding Shares: 96.52 Million
Shares in Float: 11.80 Million
The already-low-float share structure just became even tighter, which is great news for long-term shareholders. Through mid-April, Innovest Global, Inc. (OTC Pink: IVST) has skyrocketed nearly 1,000% year-to-date, making the stock one of the best performers in 2018. Innovest Global, Inc. (OTC Pink: IVST) has an exciting future ahead and early investors will likely be awarded for their patience.
Click Here To See the Innovest Global, Inc. (OTC Pink: IVST) Earnings Alert On Spotlight Growth Live
Disclaimer:
Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.
All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated two thousand five hundred dollars cash and fifty thousand restricted shares for the creation and dissemination of this content.
This material does not represent an investment solicitation. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.
The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.
Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: https://spotlightgrowth.com//disclosures/
